Asthma and atopy in COVID-19: 2021 updates - 03/02/22

Key words : Asthma, COVID-19 disease, SARS-CoV-2, atopy
El texto completo de este artículo está disponible en PDF.
Esquema
Supported by grants from the National Institutes of Health and the American Lung Association. |
|
Disclosure of potential conflict of interest: T. F. Carr reports consulting fees from AstraZeneca, Genentech, Novartis, GSK; speaker fees from Regeneron, AstraZeneca, and Novartis; and editorial fees from UpToDate. M. Kraft reports research grants from AstraZeneca and Sanofi-Regeneron, NIH and American Lung Association paid to the University of Arizona; consulting fees from Chiesi, Astra-Zeneca, Genentech, and Sanofi-Regeneron; speaker fees from Chiesi; patents for RaeSedo, LLC, and is company founder and Chief Medical Officer; and editorial fees from UpToDate. |
Vol 149 - N° 2
P. 562-564 - février 2022 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.